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Abstract
Introduction: Although the safety of celecoxib has been investigated, limited data are available on complications
affecting the entire (upper and lower) gastrointestinal (GI) tract, with no patient-level pooled analyses of upper and
lower GI outcomes available. We therefore evaluated the upper and lower GI safety of celecoxib by using patient-
level data from randomized controlled trials (RCTs).
Methods: This patient-level pooled analysis included 52 prospective, randomized, double-blind parallel-group studies
from the Celecoxib Clinical Database. Each study had a planned duration of continuous treatment with celecoxib or a
nonselective nonsteroidal antiinflammatory drug (nsNSAID), rofecoxib, or the placebo comparator arm for at least 4
weeks. All studies with final reports completed by 1 October 2007 were included. The primary end point was the
combined incidence of clinically significant upper and lower GI events (CSULGIEs). An independent blinded committee
reviewed and adjudicated all end points by using predefined criteria and all available reported adverse events,
laboratory data, and case narratives. All doses of celecoxib and all doses of all nsNSAIDs were pooled for analysis.
Results: The pooled analysis involved 51,048 patients; 28,614 were randomized to celecoxib; 15,278 to nsNSAIDs
(including 3,248 patients taking naproxen, 2,640 taking ibuprofen, 8,066 taking diclofenac, 1,234 taking loxoprofen,
and 90 taking ketoprofen); 5,827 to placebo and 1,329 to rofecoxib. The mean age was 60 years, and 65% were
women. Data on 1,042 patients with potential GI events were reviewed for end-points adjudication; the
adjudication committee confirmed 89 patients with CSULGIEs. The majority were in the celecoxib and nsNSAID
groups (with raw incidence proportions of 37 (0.1%) and 40 (0.3%), respectively). The incidence rates were 0.3, 0.9
and 0.3 per 100 patient-years in the celecoxib, nsNSAID, and placebo groups, respectively. The time to incidence of
CSULGIEs was significantly longer with celecoxib than with nsNSAIDs (P = 0.0004).
Conclusions: When compared with nsNSAIDs, celecoxib is associated with a significantly lower risk of all clinically
significant GI events throughout the entire GI tract. This pooled analysis of 52 RCTs significantly advances the
understanding of the upper and lower GI safety profile of celecoxib and its potential benefits to patients.
Introduction
Patients seeking effective pain relief from chronic and
acute painful conditions such as osteoarthritis (OA), rheu-
matoid arthritis (RA), postsurgical pain, and dysmenorrhea
may be prescribed nonselective (ns) nonsteroidal
antiinflammatory drugs (NSAIDs) (for example, naproxen,
diclofenac, and ibuprofen) or cyclooxygenase (COX)-2
selective NSAIDs (for example, celecoxib). The benefits
and risks of each medication vary according to both the
clinical setting and individual patient characteristics. Some
patients respond well to NSAID use, whereas others
receive little benefit [1]. However, all patients using
NSAIDs run the risk of associated adverse events (AEs).
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The AEs associated with NSAID use include upper
and lower gastrointestinal (GI) adverse outcomes [2-6]
and cardiovascular events [7-10]. Assessment of both
upper- and lower-GI complications is important, as a
number of studies have shown that the use of NSAIDs
increases the risk of lower-GI AEs [5,11,12]. The novel
end point of clinically significant upper-and lower-GI
events (CSULGIEs) extends the traditional assessment
of upper-GI complications (perforations, obstructions
and bleeding in the esophagus, stomach, and duode-
num) by also including events (perforation, bleeding,
and clinically significant anemia) from the lower-GI
tract (small/large bowel) [2].
Unlike nsNSAIDs that inhibit both the constitutive
and inducible forms of the COX enzyme (COX-1 and
COX-2), celecoxib is selective for the COX-2 enzyme.
Inhibition of the COX-1 enzyme is responsible for the
associated GI toxicity of nsNSAIDs [13], and the selec-
tive COX-2 inhibitory activity of celecoxib is believed to
be associated with a lower risk of GI AEs than are the
nsNSAIDs [14].
The GI safety of celecoxib has been investigated in
observational studies, randomized controlled trials
(RCTs), and meta-analyses of RCTs. An observational
study found a lower short-term risk of upper-GI toxicity
for celecoxib than for nsNSAIDs, as measured in hospita-
lization rates due to upper-GI bleeds [15]. Two large
RCTs, Celecoxib Long-term Arthritis Safety Study
(CLASS) and SUccessive Celecoxib Efficacy and Safety
Study (SUCCESS), compared the GI safety of celecoxib
with that of nsNSAIDs by using the upper-GI ulcer-com-
plications measurement. CLASS found celecoxib to be no
different from comparator nsNSAIDs in the incidence of
upper-GI ulcer complications [16], whereas SUCCESS
showed superior GI safety of celecoxib over nsNSAIDs
[17]. A third large RCT, Celecoxib vs Omeprazole and
Diclofenac in Patients with Osteoarthritis and Rheuma-
toid Arthritis (CONDOR), compared the total (upper
and lower) GI safety of celecoxib with that of the
nsNSAID diclofenac in patients with OA and RA at
increased gastrointestinal risk. This was the first clinical
trial to show that the risk of clinical outcomes through-
out the GI tract was significantly reduced in patients
treated with celecoxib compared with diclofenac-treated
patients [18].
Meta-analyses of RCTs, comparing celecoxib with
nsNSAIDs for upper-GI events, also concluded that cele-
coxib is superior to comparator nsNSAIDs for GI safety
[19-21]. The review by Deeks et al. (2002) was limited to
nine trials and 15,187 patients; the review by Moore et al.
(2005) was a more comprehensive analysis of 31 RCTs
and 39,605 patients based on Pfizer study reports, but did
not assess ulcer complications; and the Rostom et al.
(2007) review was not limited to celecoxib trials. None of
these meta-analyses, however, included patient-level data
with independent adjudication.
Although the safety of celecoxib has previously been
investigated in observational studies, RCTs, and meta-
analyses, limited data are available on complications
affecting the entire (upper and lower) GI tract. To date,
no patient-level comprehensive meta-analysis or pooled
analysis of both upper- and lower-GI outcomes with
COX-2 selective NSAIDs has been published. The pre-
sent pooled analysis evaluating the upper- and lower-GI
safety of celecoxib in RCTs fills this evidence gap.
Methods
Clinical studies
All clinical studies from the Pfizer Celecoxib Clinical
Database meeting the following criteria were identified
and included in the pooled analysis: (a) randomized,
double-blind studies with a parallel-group design; (b)
one treatment arm was celecoxib with placebo or
nsNSAID comparator; (c) planned duration of continu-
ous treatment ≥ 4 weeks; and (d) final study report
completed by 1 October 2007. Open-label, crossover
trials, and all studies of healthy volunteers were
excluded from the pooled analysis.
At the time of the analysis, Pfizer was concurrently
conducting large clinical research programs (with up to
30,000 subjects) to assess GI and/or cardiovascular
events associated with the use of celecoxib and com-
monly used NSAIDs. However, because CONDOR
(NCT00141102) [18], Gastrointestinal Randomized
Event And Safety Open-Label NSAID Study (GI-REA-
SONS; NCT00373685) and the Prospective Randomized
Evaluation of Celecoxib Integrated Safety Vs Ibuprofen
or Naproxen (PRECISION; NCT00346216) trial were
ongoing at the time of analysis, data from these studies
were not available for inclusion in the pooled analysis
presented here.
Outcome measures
The primary end point was the cumulative incidence of
CSULGIEs (including adjudicated perforations, obstruc-
tions, and clinically significant bleeds (defined as overt
bleeds or a decrease in hemoglobin of ≥ 2 g/dl and/or
hematocrit ≥ 10% of GI origin)). The definition of CSUL-
GIE used by the independent adjudication committee
was that proposed by Chan and colleagues (Table 1) [2].
Secondary end points included the incidence of CSUL-
GIEs or symptomatic ulcers in patients with or without
a hemoglobin decrease ≥ 2 g/dl of GI-related or poten-
tial GI cause.
GI end-point adjudication committee
An independent blinded expert committee adjudicated
all end points by using predefined GI-complications
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criteria (gastroduodenal, small bowel, or large bowel
perforation; gastric outlet obstruction; gastroduodenal
hemorrhage; large bowel hemorrhage; small bowel
hemorrhage; clinically significant anemia of defined GI
origin; acute GI hemorrhage of unknown origin, includ-
ing presumed small bowel hemorrhage; and clinically
significant anemia of presumed occult GI origin, includ-
ing possible small bowel blood loss) as well as available
reported AEs, laboratory data, vital signs, and case nar-
ratives, where available.
The adjudication committee consisted of two external,
independent gastroenterologists and one external inde-
pendent rheumatologist. The two gastroenterologists
acted as adjudicators, and the rheumatologist acted as a
facilitator only for cases in which agreement was not
initially reached between the adjudicators. The adjudica-
tors advised on the proper definition of potential and
suspected outcomes; they provided guidance on the
selection of events to be adjudicated, guidance regarding
evaluation, and collection of information necessary to
adjudicate suspected GI outcomes and guidance on the
screening methods to be applied to potential events
before adjudication. Additionally, the adjudicators vali-
dated the screening method of the potential events,
reviewed, in a blinded fashion, and where necessary,
rereviewed all suspected GI outcomes by using the clini-
cal information supplied in supporting documentation,
and provided final classification of the primary and sec-
ondary events as an end point or not an end point.
Adjudication of CSULGIEs could be made satisfactorily
only when clinical information in the form of a narrative
was available. The facilitator coordinated consensus
between adjudicators in cases of discordance, but did
not adjudicate any end points.
Statistical analysis
Subjects were included in the safety analysis if they were
randomized and treated with one or more doses of
study medication. All doses of celecoxib (from < 200 to
800 mg total daily dose), and all doses of all nsNSAIDs
were pooled for analysis. Tabulations and descriptive
statistics were used to summarize end points of interest;
95% confidence intervals are presented, if applicable,
and all hypothesis testing was two-sided, with a signifi-
cance level of 5%.
Statistical procedure LIFETEST in SAS software (Ver-
sion 8 of the SAS System) was used to compute and
plot the estimate of the distribution of the survival time
(that is, the Kaplan-Meier curve). A stratified log-rank
test was used to compare treatments, adjusting for
studies.
In addition to the raw events, exposure-adjusted inci-
dence rates (number of patients with events per 100
years of exposure) were calculated to account for poten-
tial differences between groups in duration of exposure
to treatment. The incidence rates were calculated by
dividing the number of adjudicated GI events by the




Fifty-two studies were identified as meeting the selection
criteria (see Additional file 1). Of these, 37 studies were
in OA/RA, involving 41,638 (82%) patients; five studies
in chronic low-back pain involved 3,635 (7%) patients,
four in ankylosing spondylitis involved 1,644 (3%)
patients, three in Alzheimer disease involved 487 (1%)
patients, and three in oncology involved 3,644 (7%)
patients. The mean age was about 60 years, and 65%
were women.
As shown in Table 2 and Figure 1, 51,048 patients
were included in this pooled analysis; 28,614 patients
were randomized to celecoxib (875 patients taking <
200 mg, 12,835 taking 200 mg, 9,616 taking 400 mg,
and 5,288 taking 800 mg total daily dose); 15,278 to
nsNSAIDs (including 3,248 patients taking naproxen,
2,640 taking ibuprofen, 8,066 taking diclofenac, 1,234
taking loxoprofen, and 90 taking ketoprofen); 5,827 to
placebo, and 1,329 to rofecoxib. The majority (60%) of
Table 1 Clinically significant upper- and lower-GI events (CSULGIEs) composite end point
With lesion Without lesion
GD hemorrhage Acute hemorrhage of unknown origin, including presumed small bowel hemorrhage
Gastric-outlet obstruction Clinically significant anemia of presumed occult GI origin, including possible small bowel blood loss




Clinically significant anemia of defined GI origin
Symptomatic ulcers
GD, gastroduodenal; GI, gastrointestinal.
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the trials were ≤ 12 weeks in duration. The total
patient-years of exposure were 20,808: 12,276 years in
the celecoxib group, 4,622 years in the nsNSAID group,
3,756 years in the placebo group, and 155 years in the
rofecoxib group.
In total, 1,042 patients with either a reported serious
GI event (354 patients) or with a hemoglobin decrease ≥
2 g/dl (688 patients; Figure 1) were sent for adjudication
(celecoxib n = 489 (2%); nsNSAIDs n = 456 (3.0%); pla-
cebo n = 92 (1.6%); rofecoxib n = 5 (0.4%)). Of the 354
serious GI cases with narratives, 203 (0.7%) were in the
celecoxib group, 104 (0.7%) in the nsNSAID group, 46
(0.8%) in the placebo group, and 1 (0.1%) in the rofe-
coxib group. The 688 patients with a decrease in hemo-
globin ≥ 2 g/dl without a narrative were adjudicated
based on additional information, including AEs, labora-
tory values, and vital signs. The majority of these
patients were from the celecoxib (286 (1.0%)) and
nsNSAIDs groups (352 (2.3%)), followed by the placebo
(46 (0.8%)) and rofecoxib groups (4 (0.3%)).
Primary end point: incidence of CSULGIEs
Of the 354 patients with narratives, the adjudication
committee confirmed 89 patients with CSULGIEs
(Table 3). The majority of these patients were in the cel-
ecoxib and nsNSAID groups (37 (0.1%) and 40 (0.3%)
patients, respectively). The remaining 12 patients were
from the placebo groups. The incidence rates were 0.3,
0.9, and 0.3 per 100 patient-years in the celecoxib,
nsNSAID, and placebo groups, respectively (Figure 2).
The time to incidence of CSULGIEs was significantly
longer with celecoxib than with nsNSAIDs (P = 0.0004)
(Figure 3).
Secondary end points
Incidence of CSULGIES or symptomatic ulcers
The adjudication committee confirmed a CSULGIE or
symptomatic ulcer in 103 of 354 patients with narratives
(47 (0.2%) patients in celecoxib, 44 (0.3%) in nsNSAID,
and 12 (0.2%) in placebo groups) (Table 3). The inci-
dence rates were 0.4, 1.0, and 0.3 per 100 patient-years
in the celecoxib, nsNSAID, and placebo groups, respec-
tively (Figure 2). The time to incidence of CSULGIEs
was significantly longer with celecoxib than with
nsNSAIDs (P = 0.0006) (see Additional file 2).
Incidence of CSULGIES, or symptomatic ulcers, or
hemoglobin decrease ≥ 2 g/dl
Of the 688 patients who had a decrease in hemoglobin ≥
2 g/dl, the adjudication committee confirmed 577
patients as having significant bleeds of GI-related or
potential GI cause. Combining with those CSULGIEs and
symptomatic ulcers, a total of 680 patients met this sec-
ondary end point (Table 3). The majority of these
patients were in the celecoxib and nsNSAID groups (281
and 343 patients, respectively). The remaining 56 patients
were from the placebo (52 patients) and rofecoxib (four












Mean, SD 60.1 (13) 59.3 (13) 57.2 (14) 70.6 (9) 59.8 (13)
≥ 65 years, n (%) 11,404 (40) 5,667 (37) 1,901 (33) 1,115 (84) 20,087 (39)
≥ 75 years, n (%) 3,421 (12) 1,656 (11) 513 (9) 460 (35) 6,050 (12)
Female, n (%) 18,819 (66) 10,478 (69) 3,251 (56) 860 (65) 33,408 (65)
Indication
OA/RA, n (%) 23,324 (82) 13,911 (91) 3,074 (53) 1,329 (100) 41,638 (82)
Low-back pain, n (%) 1,743 (6) 850 (6) 1,042 (18) 0 (0) 3,635 (7)
Ankylosing spondylitis, n (%) 895 (3) 517 (3) 232 (4) 0 (0) 1,644 (3)
Alzheimer disease, n (%) 329 (1) 0 (0) 158 (3) 0 (0) 487 (1)
Oncology, n (%) 2,323 (8) 0 (0) 1,321 (23) 0 (0) 3,644 (7)
Duration, n (%)
≤ 12 weeks 15,597 (55) 8,322 (55) 3,871 (66) 1,245 (94) 29,035 (57)
> 12 and ≤ 26 weeks 7,878 (28) 4,271 (28) 675 (12) 84 (6) 12,908 (25)
> 26 and ≤ 52 weeks 2,307 (8) 1,958 (13) 90 (2) 0 (0) 4,355 (9)
≥ 52 weeks 2,832 (10) 727 (5) 1,191 (20) 0 (0) 4,750 (9)
Total patient-years of exposure 12,276.3 4,621.8 3,755.6 154.5 20,808.2
100 patient-years of exposure 122.8 46.2 37.6 1.6 208.1
100 Patient-years of exposure = total patient-years of exposure divided by 100. nsNSAID, nonselective nonsteroidal antiinflammatory drug; OA, osteoarthritis; RA,
rheumatoid arthritis.
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patients) groups. The incidence rates were 2.3, 7.4, 1.4,
and 2.6 per 100 patient-years in the celecoxib, nsNSAID,
placebo, and rofecoxib groups, respectively (Figure 2).
The time to incidence of CSULGIEs was significantly
longer with celecoxib than with nsNSAID (P < 0.0001)
(see Additional file 3).
Discussion
The findings of this retrospective pooled analysis of 52
RCTs and more than 51,000 patients show that
celecoxib is associated with a significantly lower risk of
all clinically significant GI events throughout the entire
GI tract when compared with nsNSAIDs, however
defined. This is consistent with previously published
meta-analyses [19-21] and observational studies [15,22].
A major strength of this patient-level pooled analysis
was the inclusion of more than 51,000 patients with
active disease (OA/RA, chronic low-back pain, ankylos-
ing spondylitis, Alzheimer disease, or cancer), giving a
robust sample size. It included all the methodologically
Figure 1 Incidence of CSULGIEs. AEs, adverse events; CSULGIEs, clinically significant upper and lower GI events; GI, gastrointestinal; nsNSAID,
nonselective nonsteroidal antiinflammatory drug.











CSULGIEs, n (%) 37 (0.1) 40 (0.3) 12 (0.2) 0 (0) 89 (0.2)
Incidence ratea 0.3 0.9 0.3 0 0.4
CSULGIEs or symptomatic ulcers, n (%) 47 (0.2) 44 (0.3) 12 (0.2) 0 (0) 103 (0.2)
Incidence ratea 0.4 1.0 0.3 0 0.5
CSULGIEs, symptomatic ulcers, or hemoglobin decrease, n (%) 281 (1.0) 343 (2.3) 52 (0.9) 4 (0.3) 680 (1.3)
Incidence ratea 2.3 7.4 1.4 2.6 3.3
aIncidence rate based on 100 patient-years of exposure to drug. CSULGIEs, clinically significant upper and lower GI events; nsNSAID, nonselective nonsteroidal
antiinflammatory drug.
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sound randomized trials of celecoxib performed of at
least 4 weeks’ duration and concluded by October 2007.
Further strengths included the independent evaluation
of both upper- and lower-GI complications, together
with the blinded adjudication of cases.
Caution should be exercised, however, because many
of the clinical trials included in this analysis were not
designed to study serious GI outcomes, and, at the time,
detailed clinical information was not available on all sus-
pected end points. In addition, the quality and the avail-
ability of the narratives varied (that is, some narratives
were not available, and some were more fully descriptive
of the serious AEs than were others). The members of
the adjudication committee used their best clinical judg-
ments based on available data for these adjudications.
Furthermore, analysis of trials solely from the Pfizer Cel-
ecoxib Clinical Database might exclude relevant trials
conducted elsewhere.
One additional issue is that the number of primary
outcome events (patients experiencing CSULGIEs) was,
at 89, below the limits of about 200 to eliminate ran-
dom-chance effects suggested for adverse-event determi-
nations [23]. For secondary outcomes, the number of
events was > 200. The primary and secondary events
were influenced in the same direction and to much the
same extent.
Statistical heterogeneity between trials is not unex-
pected when the number of events is small, as in the
case of rare adverse events [24]. The primary analysis
method using a stratified log-rank test adjusting for stu-
dies was prespecified. Small numbers of events produce
uncertainty over results [25], with subgroup analysis
based on small numbers producing incorrect results;
therefore, the advice is not to consider subgroup ana-
lyses in this circumstance [26]. For these reasons,
together with the adjudication of CSULGIEs as a speci-
fic definition rather than by site of injury (upper or
lower gastrointestinal tract), no subgroup analyses were
attempted.
Systematic reviews generally should have a cut-off date
beyond which additional information for new studies is
not added. This is especially necessary when a detailed
program of adjudication is required, as it was for this
analysis of more than 1,000 patients. Medicines like cel-
ecoxib, with ongoing investigations into their benefits
and safety, require the findings from meta-analyses to
be continually compared with results from studies com-
pleted after the meta-analysis study inclusion cut-off
date. This is particularly the case when the number of
patients exposed or the duration of exposure would
have added significantly to the total number available in
the meta-analysis: here, 28,614 patients were exposed to
celecoxib for 12,276 years. Several studies that were
completed after the cut-off date are relevant, and show
similar trends (Figure 4)
A large clinical research program of three studies
(CONDOR, GI-REASONS, and PRECISION) to assess
both the GI and/or cardiovascular safety of celecoxib
Figure 2 Incidence rate (per 100 patient-years) of CSULGIEs.
Hb, hemoglobin; nsNSAID, nonselective nonsteroidal
antiinflammatory drug; SU, symptomatic ulcer.
Figure 3 Kaplan-Meier plot of time to incidence of CSULGIEs. nsNSAID, nonselective nonsteroidal antiinflammatory drug.
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and commonly used nsNSAIDs was ongoing at the cut-
off date of this meta-analysis. The CONDOR and GI-
REASONS studies have now been completed, whereas
the PRECISION trial is still ongoing. The CONDOR
trial, which compared the total GI safety of celecoxib
with diclofenac plus omeprazole by using the novel
composite GI end point of CSULGIEs, was completed in
May 2009 [18]. OA and RA patients (n = 4,484) were
randomized either to celecoxib or to diclofenac plus
omeprazole for 6 months. The rate of CSULGIEs was
significantly lower with celecoxib than with diclofenac
plus omeprazole (0.9% versus 3.8%), and the majority of
the events were related to anemia (decrease in hemoglo-
bin ≥ 2 g/dl).
The GI-REASONS study, which was completed in
November 2010, assessed the incidence of CSULGIEs in
OA patients (n = 8,067) randomized to celecoxib or
nsNSAIDs for 6 months [27]. The rate of CSULGIEs
was significantly lower with celecoxib (1.3%) than with
nsNSAIDs (2.4%), and the majority of events were also
related to anemia (decrease in hemoglobin, ≥ 2 g/dl).
These two studies used the same end point as did our
meta-analysis, used an adjudication committee, and
reached essentially the same conclusion, that celecoxib
was associated with a significantly lower rate of GI tract
events than were nsNSAIDs. Other trials involving cele-
coxib have been reported since 2007, but none of a size
or concentration on GI-tract outcomes that would allow
comparison with results from our meta-analysis.
Conclusions
When compared with nsNSAIDs, celecoxib is associated
with a significantly lower risk of all clinically significant
GI events throughout the entire GI tract. This pooled
analysis of patient-level data from 52 RCTs significantly
advances the understanding of the cumulative upper-
and lower-GI safety profile of celecoxib and its potential
benefits to patients. Future NSAID safety studies should
consider analyzing the cumulative incidence of clinically
significant upper- and lower-GI events.
Additional material
Additional file 1: Clinical studies included in the pooled analysis. A
list containing the clinical studies included in the pooled analysis and
the duration of treatment and treatment groups of each clinical study.
Additional file 2: Kaplan-Meier plot of time to incidence of
CSULGIEs or symptomatic ulcers. The time to incidence of CSULGIEs
was significantly longer with celecoxib than with nsNSAIDs. CSULGIEs,
clinically significant upper and lower GI events; nsNSAID, nonselective
nonsteroidal antiinflammatory drug.
Additional file 3: Kaplan-Meier plot of time to incidence of
CSULGIEs, symptomatic ulcers, or hemoglobin decrease ≥ 2 g/dl of
GI-related or potential GI cause. The time to incidence of CSULGIEs
was significantly longer with celecoxib than with nsNSAIDs. CSULGIEs,
clinically significant upper- and lower-GI events; GI, gastrointestinal;
nsNSAID, nonselective nonsteroidal antiinflammatory drug.
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